Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer

Gynecologic Oncology

Volumn 122, Issue 3, 2011, Pages 573-579

  De Stefano, Ilaria ^a   Zannoni, Gian Franco ^a   Prisco, Maria Grazia ^a   Fagotti, Anna ^a   Tortorella, Lucia ^a   Vizzielli, Giuseppe ^a   Mencaglia, Luca ^b   Scambia, Giovanni ^a   Gallo, Daniela ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Villanova Hospital of Firenze   (Italy)

Author keywords

Epithelial ovarian carcinomas; ER ; ER ; Ovary; PR; Survival

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PROGESTERONE RECEPTOR;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EPITHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEROUS OVARIAN CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CELL NUCLEUS; CISPLATIN; COHORT STUDIES; CYSTADENOCARCINOMA, SEROUS; CYTOPLASM; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; RECEPTORS, PROGESTERONE;

EID: 80051549162     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.05.025     Document Type: Article

References (50)

1. J. Ferlay, P. Autier, M. Boniol, M. Heanue, M. Colombet, and P. Boyle Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol 18 2007 581 592 (Pubitemid 46359643)
2. A. Jemal, R. Siegel, J. Xu, and E. Ward 2010 Cancer statistics CA Cancer J Clin 60 2010 277 300
3. L.W. Rice Hormone prevention strategies for breast, endometrial and ovarian cancers Gynecol Oncol 118 2010 202 207
4. S.A. Cannistra Cancer of the ovary N Engl J Med 351 2004 2519 2529 Review
5. A. Gadducci, S. Cosio, R. Tana, and A.R. Genazzani Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer Crit Rev Oncol Hematol 69 2009 12 27
6. A.J. O'Donnell, K.G. Macleod, D.J. Burns, J.F. Smyth, and S.P. Langdon Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen Endocr Relat Cancer 12 2005 851 866 (Pubitemid 41815780)
7. O. Treeck, G. Pfeiler, D. Mitter, C. Lattrich, G. Piendl, and O. Ortmann Estrogen receptor {beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells J Endocrinol 193 2007 421 433 (Pubitemid 47028693)
8. A. Bardin, N. Boulle, G. Lazennec, F. Vignon, and P. Pujol Loss of ERbeta expression as a common step in estrogen-dependent tumor progression Endocr Relat Cancer 11 2004 537 551 Review (Pubitemid 39331282)
9. J. Matthews, and J.A. Gustafsson Estrogen signaling: a subtle balance between ER alpha and ER beta Mol Interv 3 2003 281 292 Review
10. N. Levy, S. Paruthiyil, X. Zhao, O.I. Vivar, E.F. Saunier, and C. Griffin Unliganded estrogen receptor-beta regulation of genes is inhibited by tamoxifen Mol Cell Endocrinol 315 2010 201 207
11. C. Zhao, K. Dahlman-Wright, and J.A. Gustafsson Estrogen receptor beta: an overview and update Nucl Recept Signal 1 6 2008 e003
12. A.M. Shaaban, A.R. Green, S. Karthik, Y. Alizadeh, T.A. Hughes, and L. Harkins Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients Clin Cancer Res 14 2008 5228 5235
13. Y.K. Leung, H.M. Lam, S. Wu, D. Song, L. Levin, and L. Cheng Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion Endocr Relat Cancer 17 2010 675 689
14. L.P. Stabile, S. Dacic, S.R. Land, D.E. Lenzner, R. Dhir, and M. Acquafondata Combined analysis of estrogen receptor {beta}-1 and progesterone receptor expression identifies lung cancer patients with poor outcome Clin Cancer Res 17 2011 154 164
15. G.F. Zannoni, M.G. Prisco, V.G. Vellone, I. De Stefano, G. Scambia, and D. Gallo Changes in the expression of oestrogen receptors and E-cadherin as molecular markers of progression from normal epithelium to invasive cancer in elderly patients with vulvar squamous cell carcinoma: a pilot study Histopathology 58 2011 265 275
16. Zannoni GF, Prisco MG, Vellone VG, De Stefano I, Vizzielli G, Tortorella L, et al. Cytoplasmic expression of Estrogen Receptor beta (ERβ) as a prognostic factor in vulvar squamous cell carcinoma in elderly women. Histopathology (in press).
17. R.J. Pietras, and D.C. Márquez-Garbán Membrane-associated estrogen receptor signaling pathways in human cancers Clin Cancer Res 13 2007 4672 4676 (Pubitemid 47294772)
18. G. Scambia, G. Ferrandina, G. D'Agostino, A. Fagotti, M. Di Stefano, and F. Fanfani Oestrogen and progesterone receptors in ovarian carcinoma Endocr Relat Cancer 5 1998 293 301 (Pubitemid 29030269)
19. A.E. Drummond Fuller PJ The importance of ERbeta signalling in the ovary J Endocrinol 205 2010 15 23
20. G.J. Rustin Use of CA-125 to assess response to new agents in ovarian cancer trials J Clin Oncol 21 2003 187 193
21. G.J. Rustin, M. Quinn, T. Thigpen, A. du Bois, E. Pujade-Lauraine, and A. Jakobsen Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) J Natl Cancer Inst 96 2004 487 488 (Pubitemid 38443654)
22. M. Fung-Kee-Fung, T. Oliver, L. Elit, A. Oza, H.W. Hirte, and P. Bryson Optimal chemotherapy treatment for women with recurrent ovarian cancer Curr Oncol 14 2007 195 208
23. A.M. Gown Current issues in ER and HER2 testing by IHC in breast cancer Mod Pathol 21 Suppl 2 2008 S8 S15
24. G.E. Weitsman, G. Skliris, K. Ung, B. Peng, M. Younes, and P.H. Watson Assessment of multiple different estrogen receptor-beta antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions Breast Cancer Res Treat 100 2006 23 31
25. M. Ibrahim, A. Dodson, S. Barnett, D. Fish, B. Jasani, and K. Miller Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2): findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory Am J Clin Pathol 129 2008 398 409 (Pubitemid 352029292)
26. M.A. Hayat Estrogens Microscopy, immunohistochemistry, and antigen retrieval methods for light and electron microscopy 2002 Kluwer Academic/Plenum Publishers New York, NY 276 277
27. R. Emig, A. Magener, V. Ehemann, A. Meyer, F. Stilgenbauer, and M. Volkmann Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation Br J Cancer 78 1998 1661 1668 (Pubitemid 28550055)
28. R. von Wasielewski, M. Mengel, B. Wiese, T. Rüdiger, H.K. Müller-Hermelink, and H. Kreipe Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial Am J Clin Pathol 118 2002 675 682 (Pubitemid 37046311)
29. N. Shabani, C. Kuhn, S. Kunze, S. Schulze, D. Mayr, and D. Dian Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas Eur J Cancer 43 2007 2434 2444 (Pubitemid 350001248)
30. A. Burges, A. Brüning, C. Dannenmann, T. Blankenstein, U. Jeschke, and N. Shabani Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovary Arch Gynecol Obstet 281 2010 511 517
31. A. du Bois, A. Reuss, E. Pujade-Lauraine, P. Harter, I. Ray-Coquard, and J. Pfisterer Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) Cancer 115 2009 1234 1244
32. R. Halperin, S. Zehavi, E. Hadas, L. Habler, I. Bukovsky, and D. Schneider Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma Int J Gynecol Pathol 20 2001 341 345 (Pubitemid 32937448)
33. P.R. Lindgren, S. Cajander, T. Bäckström, J.A. Gustafsson, S. Mäkelä, and J.I. Olofsson Estrogen and progesterone receptors in ovarian epithelial tumors Mol Cell Endocrinol 221 2004 97 104 (Pubitemid 38829727)
34. D.G. Rosen, X. Huang, M.T. Deavers, A. Malpica, E.G. Silva, and J. Liu Validation of tissue microarray technology in ovarian carcinoma Mod Pathol 17 2004 790 797 (Pubitemid 38843361)
35. N.G. Ordóñez Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas Hum Pathol 36 2005 1163 1167 (Pubitemid 41541966)
36. S.M. Ho Estrogen, progesterone and epithelial ovarian cancer Reprod Biol Endocrinol 7 1 2003 73 Review
37. S. Cunat, P. Hoffmann, and P. Pujol Estrogens and epithelial ovarian cancer Gynecol Oncol 94 2004 25 32 Review (Pubitemid 38950494)
38. K.K. Chan, N. Wei, S.S. Liu, L. Xiao-Yun, A.N. Cheung, and H.Y. Ngan Estrogen receptor subtypes in ovarian cancer: a clinical correlation Obstet Gynecol 111 2008 144 151
39. G. Scambia, P. Benedetti-Panici, G. Ferrandina, M. Distefano, G. Salerno, and M.E. Romanini Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy Br J Cancer 72 1995 361 366
40. P. Lee, D.G. Rosen, C. Zhu, and E.G. Silva Liu J Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer Gynecol Oncol 96 2005 671 677 (Pubitemid 40255486)
41. E.V. Høgdall, L. Christensen, C.K. Høgdall, J. Blaakaer, S. Gayther, and I.J. Jacobs Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study Oncol Rep 18 2007 1051 1059
42. J. Akahira, T. Inoue, T. Suzuki, K. Ito, R. Konno, and S. Sato Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies Br J Cancer 83 2000 1488 1494
43. S. Mozzetti, C. Ferlini, P. Concolino, F. Filippetti, G. Raspaglio, and S. Prislei Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients Clin Cancer Res 11 2005 298 305 (Pubitemid 40075808)
44. J. Saussede-Aim, E.L. Matera, C. Ferlini, and C. Dumontet Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway Cell Motil Cytoskeleton 66 2009 378 388
45. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 2002 1248 1259 (Pubitemid 34177431)
46. R.W. Hunter, N.D. Alexander, and W.P. Soutter Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 166 1992 504 511
47. M. Markman Concept of optimal surgical cytoreduction in advanced ovarian cancer: a brief critique and a call for action J Clin Oncol 25 2007 4168 4170 (Pubitemid 47548554)
48. L.N. Abaid, B.H. Goldstein, K.L. Lopez, J.P. Micha, J.V. Brown 3rd, and M.A. Rettenmaier The prognostic significance of optimal debulking in the setting of a complete clinical response for advanced ovarian carcinoma patients receiving maintenance chemotherapy Arch Gynecol Obstet 283 2011 1127 1131
49. O. Imamov, G.J. Shim, M. Warner, and J.A. Gustafsson Estrogen receptor beta in health and disease Biol Reprod 73 2005 866 871 (Pubitemid 41507488)
50. T.A. Blizzard Selective estrogen receptor modulator medicinal chemistry at Merck. A review Curr Top Med Chem 8 2008 792 812 Review (Pubitemid 351982567)